IntelGenx Corp. (OTCQB: IGXT) announced a Notice of Allowance from the USPTO for its US Patent Application 16/110,737, covering a novel film dosage form for drug delivery. This patent is significant for the company's DisinteQ™ products, which enhance transmucosal absorption of THC by minimizing first-pass metabolism. CEO Dr. Horst G. Zerbe highlighted the timing as favorable due to industry interest in this technology, positioning IntelGenx as a leader in the cannabis oral film sector.
IntelGenx Corp. (TSX-V:IGX) has filed a new provisional patent application for its "High Loading Oral Film Formulation" with the U.S. Patent and Trademark Office. This patent aims to enhance the incorporation of high concentrations of active ingredients into its VetaFilm™ technology, achieving a 1-to-1 active-to-polymer ratio. The development follows promising blood level results from a feasibility study with a major animal health company and supports IntelGenx's position in the oral veterinary film market. The company continues to focus on innovative drug delivery solutions for unmet medical needs.
IntelGenx Technologies Corp. (TSX-V:IGX, OTCQB:IGXT) has successfully closed a private placement offering, raising U.S.$1.2 million through 8% convertible notes due October 15, 2024. The notes will bear an 8% annual interest rate, payable quarterly, and can convert into shares at U.S.$0.18 each starting six months post-issuance. Proceeds will be utilized for working capital. The company paid U.S.$85,000 in cash commissions and issued warrants for shares at the same conversion price. The listing of shares upon conversion is conditionally approved by TSX Venture Exchange, pending compliance with listing requirements.
ATAI Life Sciences has entered a Feasibility Agreement with IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) to develop new formulations of pharmaceutical-grade psychedelics using IntelGenx's polymeric film technologies. IntelGenx will handle pre-development and formulation work, aiming to create a prototype for ATAI's clinical trials, with potential for global commercialization. ATAI's CEO emphasized the need for efficient delivery methods for psychedelics amid a mental health crisis.